文献速递膀胱癌与上尿路尿路上皮癌

肌肉浸润性膀胱癌新辅助化疗的社会与临床相关因素:SEER-Medicare 2004-2015

Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015.
PubMed 文献 · Urology · 2020-12-26

基于 SEER-Medicare 2004-2015 年接受根治性膀胱切除术的肌肉浸润性膀胱癌患者,评估新辅助化疗(NAC)利用的社会与临床相关因素。NAC 使用率从 10.7% 升至 39.1%,但非标准方案持续存在(约 8%),且与较差生存相关。标准 NAC 较 upfront 膀胱切除术和非标准 NAC 均改善总生存。

要点

  • NAC 使用率从 2004 年 10.7% 升至 2015 年 39.1%,主要因标准方案使用增加。
  • 非标准方案最常见为吉西他滨/卡铂(50.2%),与高龄、西班牙裔和黑人种族、较低社会经济地位及顺铂禁忌相关。
  • 标准 NAC 较 upfront 膀胱切除术 OS HR 0.85(95%CI 0.76,0.94),较非标准 NAC HR 0.75(95%CI 0.63,0.89)。

核心结论

  • NAC 使用率已增至近 40%,但非标准 NAC 方案持续存在(约 8%),未提供临床获益且存在潜在 harm 风险。
  • 顺铂不耐受、高龄、种族/民族及较低社会经济地位与非标准 NAC 使用相关。
  • 依据现行指南,顺铂不耐受患者应考虑及时 upfront 膀胱切除术或新型临床试验。

研究设计与样本

  • SEER-Medicare(2004-2015)队列,纳入接受根治性膀胱切除术的肌肉浸润性膀胱癌患者 6214 例,中位随访 21(IQR 7-54)个月。
  • 患者分为三组:标准 NAC(顺铂为基础联合方案)、非标准 NAC、upfront 膀胱切除术。
  • 采用多变量 logistic 回归评估各治疗类别的社会、人口学及临床相关因素,并用倾向性匹配比较生存。

主要发现

  • NAC 使用率从 2004 年 10.7% 升至 2015 年 39.1%,主要因标准方案使用增加。
  • 非标准方案中最常见为吉西他滨/卡铂(50.2%)。
  • 高龄、西班牙裔和黑人种族、较低社会经济地位及顺铂禁忌与接受非标准 NAC(相比标准 NAC)的 odds 增加相关。
  • 标准 NAC 较 upfront 膀胱切除术 OS HR 0.85(95%CI 0.76,0.94),较非标准 NAC OS HR 0.75(95%CI 0.63,0.89)。

关键数值与推荐

  • 标准 NAC 较 upfront 膀胱切除术总生存 HR 0.85(95%CI 0.76,0.94)。
  • 标准 NAC 较非标准 NAC 总生存 HR 0.75(95%CI 0.63,0.89)。
  • 非标准 NAC 中最常见方案为吉西他滨/卡铂,占 50.2%。

临床怎么用

  • 应优先选用顺铂为基础的标准 NAC 方案,因其与改善总生存相关。
  • 对顺铂不耐受患者,非标准 NAC 未显示临床获益且可能 harm,应考虑及时 upfront 膀胱切除术或临床试验。
  • 关注高龄、少数种族/民族及较低社会经济地位患者,减少非标准 NAC 使用差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess social and clinical correlates of neoadjuvant chemotherapy (NAC) utilization among Medicare beneficiaries. MATERIALS AND METHODS: A cohort of SEER-Medicare (2004-2015) patients with muscle-invasive bladder cancer treated by radical cystectomy were stratified into 3-groups: standard of care NAC (cisplatin-based combination), non-standard of care NAC, and upfront cystectomy. Multivariable logistic regression analysis was used to assess social, demographic and clinical correlates of each treatment category. Survival analyses were performed to compare propensity matched treatment groups. RESULTS: In total, 6214 patients were identified with a median follow-up of 21 [IQR 7-54] months. NAC utilization increased from 10.7% to 39.1%, between 2004 and 2015, largely due to increased use of standard of care regimens. The most commonly used nonstandard regimen was gemcitabine/carboplatin (50.2%). Older age, Hispanic and Black race, lower socioeconomic status, and contraindications to cisplatin were associated with increased odds of receiving nonstandard of care NAC compared to standard of care. Standard of care NAC was associated with improved overall survival HR 0.85 (95% CI 0.76, 0.94) and HR 0.75 (95% CI 0.63, 0.89) compared to both upfront cystectomy and nonstandard of care NAC, respectively. CONCLUSION: NAC utilization has increased to nearly 40%; however, the use of non-standard of care NAC regimen have persisted (~8%). Cisplatin-ineligibility, older age, race/ethnicity, and lower socioeconomic status were correlated with nonstandard of care NAC, which provided no clinical benefit at the risk of potential harm. In accordance with current clinical guidelines, cisplatin-ineligible patients should be considered for timely upfront cystectomy or novel clinical trials.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Nyame YA, Holt SK, Diamontopoulos LN, et al. Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. Urology. 2020. PMID: 33373709. doi:10.1016/j.urology.2020.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。